Business Context and Reporting Period
MIMEDX GROUP, INC. filed a Form 8-K Current Report on May 22, 2008, regarding material definitive agreements entered into by its wholly-owned subsidiary, MiMedx, Inc. The filing details arrangements with Thomas J. Graham, M.D., concerning intellectual property (IP) commercialization and potential asset sales.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of specific contractual agreements.
Material Changes and Agreements
On May 22, 2008, MiMedx, Inc. and Dr. Graham executed two primary agreements:
- Revenue Sharing Agreement:
- Defines "LeveL IP" as IP contributed by Dr. Graham and related MiMedx technology.
- Dr. Graham is entitled to 20% of "Net Revenues" from any sale, license, or transfer (Disposition) of LeveL IP.
- Dr. Graham is entitled to 20% of the "Net Purchase Price" attributable to LeveL IP assets in the event of a sale of the business.
- Net Revenues/Purchase Price are calculated after deducting transaction expenses, development costs, and royalties.
- MiMedx will maintain a separate business segment, "LeveL Orthopaedics," to track these revenues.
- If no Disposition occurs within one year, the parties will mutually decide on future steps.
- Finder's Fee Agreement:
- Compensates Dr. Graham for introducing potential buyers for MiMedx assets or IP.
- Transaction fee ranges from 1% to 5% of the "Purchase Price," capped at an aggregate of $500,000.
- The agreement terminates on November 1, 2008, unless extended, though fee provisions survive for six months post-termination if a transaction occurs.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or management commentary on future earnings. The primary contingency is the potential sale or licensing of the LeveL IP assets. A key risk factor is the obligation to pay significant percentages of future proceeds (20% for IP sales, up to 5% finder's fee) to Dr. Graham, which could impact net proceeds from any future transaction. The agreements impose a timeline for potential disposition, with a review required if no sale occurs within one year.
Investor Verification Checklist
- Verify the specific scope and valuation of the "LeveL IP" assets subject to the 20% revenue share.
- Confirm the definition of "Net Revenues" and "Net Purchase Price" to understand the deductibility of expenses before the 20% share is calculated.
- Monitor the status of the "LeveL Orthopaedics" business segment for any reported revenue or disposition activity.
- Track the November 1, 2008, deadline for the Finder's Fee Agreement and any potential extensions.
- Review subsequent filings for any actual transactions involving Dr. Graham or the LeveL IP.